logo
Manu Joseph: Why drugs that eat our hunger won't cause a revolution

Manu Joseph: Why drugs that eat our hunger won't cause a revolution

Mint27-07-2025
Two drugs are generating the sort of cultural excitement that only Viagra once did. Like Viagra, their effects are visible, and often not attributed to the medicine. Semaglutide and Tirzepatide, known by their brand names Ozempic and Mounjaro, were designed to treat diabetes. But as often happens with iconic drugs, their fame lies in what they do on the side. They reduce appetite. So, people eat less and lose weight.
Doctors are taking these drugs too, which is a good sign. Not that they are paragons of health, but they know how patients respond to the drugs and so it suggests they consider them safe. Meanwhile, society is bracing for a behavioural revolution. A certain leanness—a non-muscular kind in middle-aged people that I already associate with these drugs—might become another motif of wealth. At the moment, the drugs are for the affluent, but that can change over time. There is even a view that once these drugs go off patent and generics flood the market, they may hurt the restaurant business.
Also Read: What body positivity means in the age of Ozempic
I doubt that. I think their impact will be modest. People do not eat because they're hungry, especially the rich. Even most of the poor no longer eat out of necessity alone. Nobody eats maida noodles and biryani out of hunger. For most people, eating is a form of entertainment. Even a source of happiness. Many people can bear the period between meals because they know food is coming. Many keep eating through the day because people do a lot of what is fun. Also, food is the most legit drug addiction.
Some years ago, Silicon Valley fell in love with a powdered food called Soylent. Just add water and drink. It was engineered to provide all the nutrients the body needs. As the product didn't ship to India, I found an Indian version of it. I carried packets everywhere. I was sorted, I felt. I liked the idea of just drinking food and being done with it. I had defeated an ancient cultural force that had entrapped me through what I always viewed as an obsolete mode of nutrition.
There is nothing wrong with Soylent, but its revolution never took off. People realized that life, as we've built it, revolves around food. Meals are where we meet. Efficiency is not the point. In fact, if we are efficient at all, it is in matters other than food, so that we can lavish our time on food.
At first glance, drugs that kill appetite may appear to be different from a tasteless drink that merely has everything the body needs. The drugs don't replace food. People would still eat tasty meals, even if they eat less. They would meet friends over meals, but leave most of it on their plates. At first, people will be alright with it. They are having it all, they might say. Tasty food, but in forced moderation. Eventually, though, they would have had enough of it.
Also Read: Ozempic, a patent challenge, and the $25 billion race for India's weight-loss drug market
Semaglutide and Tirzepatide cannot address the underlying reasons why people eat and overeat. Imagine a pill that makes you want to watch less TV. Let us assume it works. What is the alternative to not wasting time on boring entertainment, an oxymoron that is the reality of the times? Actually, there is something that makes you want to watch less TV, and that's TV itself. Yet, people have nothing better to do. It is the same with food. Without food, life is so dreary to most people that they will eat even if they don't feel like eating. This is something they already do, anyway.
Here is what will happen. These drugs will make the fit fitter. People who already work towards health or beauty will be the true beneficiaries of this medical intervention. Others will do things like having only desserts for meals, arguing that they are going to have little to eat anyway.
Eventually, they will find ways to malign these drugs. They will have exaggerated complaints about their side effects and romanticize 'natural' hunger. They will insist the body knows best. If it is asking for food, they will say, and if 'nature' is demanding food, then there must be some reason; how can we let 'chemicals' come in the way of natural appetite? Never underestimate the things sugar can make people do.
The effectiveness of these drugs raises an interesting question: If suppressing appetite still leaves a person healthy, then is normal eating just a form of overeating? How much food does a person really need?
Also Read: Mounjaro in India: The speed bumps impacting access to weight loss drugs
Probably far less than what most people eat. Statistically, on any given day, we over-eat or under-eat because, outside of theory, balance is not a real thing. Under-eating has its own risks. Muscle growth, for example, needs protein beyond the reduced consumption these drugs would induce. Strong muscles aren't just about vanity, they help regulate metabolism and maintain our health.
Also, when the body faces an energy deficit, it does not simply burn fat. It switches some things off. Based on its own logic and hierarchies, it starts conserving energy by cutting what it considers less important. Like one's immune response. Or skin quality. Or hair health. It adapts to scarcity by becoming stingy with its resources.
The same could happen here. People may stay lean but become weak, metabolically and bodily. We may then have unfit people who look thin. We may not understand what's been lost either. That will take years to discover.
Also Read: 'We shouldn't use Mounjaro as a way to get skinny': Dr Alexandra Sowa
If some people believe they look good just by taking a drug, they may stop working out if they have never enjoyed it. That would be a disaster. Exercise doesn't just burn fat. It does things modern life does not give us. Our true health is not what we appear to be, but what the body knows it has gone through, what it knows it can endure.
The author is a journalist, novelist, and the creator of the Netflix series, 'Decoupled'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Economic Times

time22 minutes ago

  • Economic Times

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Mint

time25 minutes ago

  • Mint

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.

66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more
66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more

Hindustan Times

time5 hours ago

  • Hindustan Times

66-year-old woman who dropped 18 kg shares 8 foods that made her ‘fat loss 10x easier': Berries, avocado, nuts and more

Ilene, a 66-year-old Instagram user, achieved an incredible weight transformation, shedding 18 kilos. What makes her journey truly inspiring is not just the weight she lost, but the fact that she accomplished it in her 60s. Ilene regularly shares glimpses of her experience, along with valuable lessons, diet tips, and lifestyle habits to help others on their own fitness journeys. Add these foods to your diet to make fat loss easier.(Shutterstock) Ilene, on June 12, shared an Instagram post to help her followers add the right kind of food items to their weight loss diet. 'Nobody told me this before I lost 40 lbs, so I'm telling you now. These foods mimic Ozempic and make fat loss 10x easier,' she wrote. Also read | Losing weight after 60: Healthy diet plan and exercise tips for seniors 1. Greek yogurt Why it helps: High-protein + fermented = big GLP-1 bump, steadier blood sugar, longer fullness. How to eat it: ¾ cup 2 % Greek yogurt + ½ cup berries + ½ scoop protein = 35 g protein breakfast or post-lift snack. 2. Sweet potatoes (especially cooled and reheated) Why it helps: Fiber + resistant starch ⟶ slower gastric emptying, steadier insulin, higher GLP-1 release. How to eat it: Roast, chill overnight, cube into salads or reheat with cinnamon and a dollop of Greek yogurt. 3. Berries Why they help: Polyphenols + fiber blunt glucose spikes and trigger satiety signals. How to eat them: Top oats, blend into protein shakes, or freeze-dry for a crunchy topping. 4. Eggs Why they help: Protein, healthy fats, and choline keep hunger hormones low and GLP-1 higher for hours. How to eat them: 2 whole eggs + ½ cup egg whites scramble → 30 g protein, add spinach for extra fiber. 5. Oats Why they help: β-glucan fiber thickens in your gut, slowing digestion and boosting GLP-1. Also read | How to lose weight after 50? Dietician shares simple steps to shed pounds and stay healthy How to eat them: ½ cup oats + water, stir in 1 scoop whey and 1 tbsp chia; microwave; top with berries ➜ protein + fiber powerhouse. 6. High-fiber veggies (broccoli, brussels sprouts, kale) Why they help: Insoluble + soluble fiber = slower carb absorption, more GLP-1, better gut health. How to eat them: Roast a sheet pan in olive oil & garlic; add to every plate (aim for 3 colors each meal). 7. Beans and lentils Why they help: Plant protein + resistant starch + fiber triple-team satiety hormones. How to eat them: ½ cup lentils in quinoa bowls or blend black beans into turkey-chili. 8. Avocado and nuts Why they help: Healthy monounsaturated fats delay gastric emptying and sustain GLP-1 signaling. How to eat them: ¼ avocado on Ezekiel toast or 10–12 almonds alongside Greek yogurt. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store